Tyrosine Kinase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2030
Get it in 2 to 4 weeks by ordering today
Tyrosine Kinase Inhibitor Trends and Forecast
The future of the global tyrosine kinase inhibitor market looks promising with opportunities in the chronic myeloid leukemia, lung cancer, breast cancer, and renal cell cancer markets. The global tyrosine kinase inhibitor market is expected to reach an estimated $86.5 billion by 2030 with a CAGR of 8.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of cancer and growing demand for targeted cancer therapies.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Tyrosine Kinase Inhibitor by Segment
The study includes a forecast for the global tyrosine kinase inhibitor by type, application, and region.
Tyrosine Kinase Inhibitor Market by Type [Shipment Analysis by Value from 2018 to 2030]:
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tyrosine kinase inhibitor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tyrosine kinase inhibitor companies profiled in this report include-
Lucintel forecasts that BCR-ABL is expected to witness highest growth over the forecast period.
Within this market, chronic myeloid leukemia is expected to witness highest growth over the forecast period.
North America will remain the largest region over the forecast period.
Features of the Global Tyrosine Kinase Inhibitor Market
Market Size Estimates: Tyrosine kinase inhibitor market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Tyrosine kinase inhibitor market size by type, application, and region in terms of value ($B).
Regional Analysis: Tyrosine kinase inhibitor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the tyrosine kinase inhibitor market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tyrosine kinase inhibitor market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the tyrosine kinase inhibitor market size?
Answer: The global tyrosine kinase inhibitor market is expected to reach an estimated $86.5 billion by 2030.
Q2. What is the growth forecast for tyrosine kinase inhibitor market?
Answer: The global tyrosine kinase inhibitor market is expected to grow with a CAGR of 8.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the tyrosine kinase inhibitor market?
Answer: The major drivers for this market are increasing prevalence of cancer and growing demand for targeted cancer therapies.
Q4. What are the major segments for tyrosine kinase inhibitor market?
Answer: The future of the tyrosine kinase inhibitor market looks promising with opportunities in the chronic myeloid leukemia, lung cancer, breast cancer, and renal cell cancer markets.
Q5. Who are the key tyrosine kinase inhibitor market companies?
Answer: Some of the key tyrosine kinase inhibitor companies are as follows:
Answer: Lucintel forecasts that BCR-ABL is expected to witness highest growth over the forecast period.
Q7. In tyrosine kinase inhibitor market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the tyrosine kinase inhibitor market by type (BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, BRAF kinase inhibitors, ROS1 inhibitors, and others), application (chronic myeloid leukemia, lung cancer, breast cancer, renal cell cancer, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Tyrosine Kinase Inhibitor Market, Tyrosine Kinase Inhibitor Market Size, Tyrosine Kinase Inhibitor Market Growth, Tyrosine Kinase Inhibitor Market Analysis, Tyrosine Kinase Inhibitor Market Report, Tyrosine Kinase Inhibitor Market Share, Tyrosine Kinase Inhibitor Market Trends, Tyrosine Kinase Inhibitor Market Forecast, Tyrosine Kinase Inhibitor Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
Tyrosine Kinase Inhibitor Trends and Forecast
The future of the global tyrosine kinase inhibitor market looks promising with opportunities in the chronic myeloid leukemia, lung cancer, breast cancer, and renal cell cancer markets. The global tyrosine kinase inhibitor market is expected to reach an estimated $86.5 billion by 2030 with a CAGR of 8.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of cancer and growing demand for targeted cancer therapies.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Tyrosine Kinase Inhibitor by Segment
The study includes a forecast for the global tyrosine kinase inhibitor by type, application, and region.
Tyrosine Kinase Inhibitor Market by Type [Shipment Analysis by Value from 2018 to 2030]:
- BCR-ABL Tyrosine Kinase Inhibitor
- Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
- Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
- Others
- Chronic Myeloid Leukemia
- Lung Cancer
- Breast Cancer
- Renal Cell Cancer
- Others
- North America
- Europe
- Asia Pacific
- The Rest of the World
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tyrosine kinase inhibitor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tyrosine kinase inhibitor companies profiled in this report include-
- AstraZeneca
- Bayer
- Boehringer Ingelheim International
- Bristol-Myers Squibb
- Eisai
- F. Hoffmann-La Roche
- Johnson and Johnson
- Novartis
- Pfizer
- Eli Lilly
Lucintel forecasts that BCR-ABL is expected to witness highest growth over the forecast period.
Within this market, chronic myeloid leukemia is expected to witness highest growth over the forecast period.
North America will remain the largest region over the forecast period.
Features of the Global Tyrosine Kinase Inhibitor Market
Market Size Estimates: Tyrosine kinase inhibitor market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Tyrosine kinase inhibitor market size by type, application, and region in terms of value ($B).
Regional Analysis: Tyrosine kinase inhibitor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the tyrosine kinase inhibitor market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tyrosine kinase inhibitor market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the tyrosine kinase inhibitor market size?
Answer: The global tyrosine kinase inhibitor market is expected to reach an estimated $86.5 billion by 2030.
Q2. What is the growth forecast for tyrosine kinase inhibitor market?
Answer: The global tyrosine kinase inhibitor market is expected to grow with a CAGR of 8.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the tyrosine kinase inhibitor market?
Answer: The major drivers for this market are increasing prevalence of cancer and growing demand for targeted cancer therapies.
Q4. What are the major segments for tyrosine kinase inhibitor market?
Answer: The future of the tyrosine kinase inhibitor market looks promising with opportunities in the chronic myeloid leukemia, lung cancer, breast cancer, and renal cell cancer markets.
Q5. Who are the key tyrosine kinase inhibitor market companies?
Answer: Some of the key tyrosine kinase inhibitor companies are as follows:
- AstraZeneca
- Bayer
- Boehringer Ingelheim International
- Bristol-Myers Squibb
- Eisai
- F. Hoffmann-La Roche
- Johnson and Johnson
- Novartis
- Pfizer
- Eli Lilly
Answer: Lucintel forecasts that BCR-ABL is expected to witness highest growth over the forecast period.
Q7. In tyrosine kinase inhibitor market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the tyrosine kinase inhibitor market by type (BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, BRAF kinase inhibitors, ROS1 inhibitors, and others), application (chronic myeloid leukemia, lung cancer, breast cancer, renal cell cancer, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Tyrosine Kinase Inhibitor Market, Tyrosine Kinase Inhibitor Market Size, Tyrosine Kinase Inhibitor Market Growth, Tyrosine Kinase Inhibitor Market Analysis, Tyrosine Kinase Inhibitor Market Report, Tyrosine Kinase Inhibitor Market Share, Tyrosine Kinase Inhibitor Market Trends, Tyrosine Kinase Inhibitor Market Forecast, Tyrosine Kinase Inhibitor Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
1. EXECUTIVE SUMMARY
2. GLOBAL TYROSINE KINASE INHIBITOR MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Tyrosine Kinase Inhibitor Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Tyrosine Kinase Inhibitor Market by Type
3.3.1: BCR-ABL Tyrosine Kinase Inhibitor
3.3.2: Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
3.3.3: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
3.3.4: Others
3.4: Global Tyrosine Kinase Inhibitor Market by Application
3.4.1: Chronic Myeloid Leukemia
3.4.2: Lung Cancer
3.4.3: Breast Cancer
3.4.4: Renal Cell Cancer
3.4.5: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Tyrosine Kinase Inhibitor Market by Region
4.2: North American Tyrosine Kinase Inhibitor Market
4.2.1:North American Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.2.2: North American Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.3: European Tyrosine Kinase Inhibitor Market
4.3.1: European Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.3.2: European Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.4: APAC Tyrosine Kinase Inhibitor Market
4.4.1: APAC Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.4.2: APAC Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.5: ROW Tyrosine Kinase Inhibitor Market
4.5.1: ROW Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.5.2: ROW Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Type
6.1.2: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Application
6.1.3: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Region
6.2: Emerging Trends in the Global Tyrosine Kinase Inhibitor Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Tyrosine Kinase Inhibitor Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Tyrosine Kinase Inhibitor Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: AstraZeneca
7.2: Bayer
7.3: Boehringer Ingelheim International
7.4: Bristol-Myers Squibb
7.5: Eisai
7.6: F. Hoffmann-La Roche
7.7: Johnson and Johnson
7.8: Novartis
7.9: Pfizer
7.10: Eli Lilly
2. GLOBAL TYROSINE KINASE INHIBITOR MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Tyrosine Kinase Inhibitor Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Tyrosine Kinase Inhibitor Market by Type
3.3.1: BCR-ABL Tyrosine Kinase Inhibitor
3.3.2: Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
3.3.3: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
3.3.4: Others
3.4: Global Tyrosine Kinase Inhibitor Market by Application
3.4.1: Chronic Myeloid Leukemia
3.4.2: Lung Cancer
3.4.3: Breast Cancer
3.4.4: Renal Cell Cancer
3.4.5: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Tyrosine Kinase Inhibitor Market by Region
4.2: North American Tyrosine Kinase Inhibitor Market
4.2.1:North American Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.2.2: North American Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.3: European Tyrosine Kinase Inhibitor Market
4.3.1: European Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.3.2: European Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.4: APAC Tyrosine Kinase Inhibitor Market
4.4.1: APAC Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.4.2: APAC Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.5: ROW Tyrosine Kinase Inhibitor Market
4.5.1: ROW Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.5.2: ROW Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Type
6.1.2: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Application
6.1.3: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Region
6.2: Emerging Trends in the Global Tyrosine Kinase Inhibitor Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Tyrosine Kinase Inhibitor Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Tyrosine Kinase Inhibitor Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: AstraZeneca
7.2: Bayer
7.3: Boehringer Ingelheim International
7.4: Bristol-Myers Squibb
7.5: Eisai
7.6: F. Hoffmann-La Roche
7.7: Johnson and Johnson
7.8: Novartis
7.9: Pfizer
7.10: Eli Lilly
